Synthetic strategy and structure-activity relationship (SAR) studies of 3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1, Lificiguat): A review

Ko Hua Yu, Hsin Yi Hung

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Since 1994, YC-1 (Lificiguat, 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole) has been synthesized, and many targets for special bioactivities have been explored, such as stimulation of platelet-soluble guanylate cyclase, indirect elevation of platelet cGMP levels, and inhibition of hypoxia-inducible factor-1 (HIF-1) and NF-κB. Recently, Riociguat®, the first soluble guanylate cyclase (sGC) stimulator drug used to treat pulmonary hypertension and pulmonary arterial hypertension, was derived from the YC-1 structure. In this review, we aim to highlight the synthesis and structure-activity relationships in the development of YC-1 analogs and their possible indications. This journal is

Original languageEnglish
Pages (from-to)251-264
Number of pages14
JournalRSC Advances
Volume12
Issue number1
DOIs
Publication statusPublished - 2021 Dec 20

All Science Journal Classification (ASJC) codes

  • Chemistry(all)
  • Chemical Engineering(all)

Fingerprint

Dive into the research topics of 'Synthetic strategy and structure-activity relationship (SAR) studies of 3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1, Lificiguat): A review'. Together they form a unique fingerprint.

Cite this